Cannabis Pharmaceuticals Market Size, Share, Trends And Forecast 2030
The global cannabis pharmaceuticals market size is expected to reach USD 127.1 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 104.2% from 2022 to 2028. Rapid growth in applications of cannabis for various indications including pain, inflammation, sleep disorders, anorexia, epilepsy, schizophrenia, and multiple sclerosis is estimated to drive market growth. There is a shift from cannabis herbal preparations to prescription drugs. Demand for processed, quantified, and packaged cannabis products is significantly increasing. Moreover, consumer, as well as regulatory acceptance of cannabis products, is increasing which in turn is positively impacting market growth.
Request Free Sample Report: https://www.grandviewresearch.com/industry-analysis/cannabis-pharmaceuticals-market
Regulatory
acceptance of cannabis products such as Sativex and Epidiolex are improving
patient and physician perspectives on cannabis as these drugs are developed and
regulated by the stringent process.
The
increasing number of research and development activities and clinical trials
for studying the therapeutic benefits of cannabis will drive the market growth
during the forecast period. For instance, in September 2020, Tilray Inc.
announced that its cannabis products are showing promising results in reducing
vomiting and nausea in patients undergoing chemotherapy for cancer. According
to the study, a quarter of the patients consuming medical cannabis did not show
nausea and vomiting. Such research studies are estimated to increase the demand
for cannabis in the pharmaceutical industry.
There
is a rise in a number of physicians prescribing cannabis to their patients due
to increasing clinical evidence, growing awareness, and an increasing number of
patients looking for cannabis as a medical alternative. For instance, according
to a survey published in 2019, 22% of the consumers were looking for replacing
prescription or OTC drugs with CBD. Moreover, 30% took CBD in addition to the
prescribed drug. Forty-seven percent replaced an OTC drug with CBD, 36% with
prescription opioids, 33% with prescription anxiety drugs, and 22% with
prescription sleep drugs. Thus, increasing cannabis consumption will drive the
pharmaceutical cannabis market globally.
Regulatory
approval of cannabis is a major parameter supporting market growth. Governments
and regulatory authorities are taking initiatives to legalize the use of
cannabis for medical purposes. For instance, In August 2020, a regulatory
authority in Portugal, INFARMED I.P., granted license to Clever Leaves for
cultivation and import export of medical cannabis. For instance, in November
2018, GW Pharmaceuticals, plc launched EPIDIOLEX (CBD) oral solution for
treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
EPIDIOLEX was approved by the FDA in June 2018. It is the first prescription
pharmaceutical formulation plant-derived CBD and an antiepileptic drug.
Cannabis
Pharmaceuticals Market Report Highlights
The Epidiolex brand type emerged as the leading application
segment in 2021, with a revenue share of 96.9% in the market
Europe dominated the market and accounted for the largest
revenue share of 43.8% in 2021
In Middle East and Africa, the market is projected to expand
at the fastest CAGR during the forecast period
Key Companies &
Market Share Insights
Key players operating in the market for cannabis pharmaceuticals
are adopting various strategies such as mergers and acquisitions and product
development to expand product portfolio and geographic presence. For instance,
in February 2021, Jazz Pharmaceuticals PLC announced its plans to acquire GW
Pharmaceuticals. Upon completion of the acquisition, Jazz Pharmaceutical would
have an enhanced neuroscience product portfolio with an increased global
commercial footprint. Some of the prominent players in the cannabis
pharmaceuticals market include:
·
GW Pharmaceuticals, plc
·
Insys Therapeutics
·
Abbvie
·
Valeant Pharmaceuticals (Bausch Health Companies, Inc.)
Browse Full Report: https://www.grandviewresearch.com/industry-analysis/cannabis-pharmaceuticals-market
Comments
Post a Comment